Pharmaceutical Technology

JUNE 30, 2022

Analysing almost eight thousand tumours across 33 different cancers, researchers say this marks the first time that a framework was created to understand the role of internal factors in driving such genomic alterations. Genomic research have greatly expanded our understanding of disease pathophysiology over the years.

Genome Project 130

Genome Project Genome Genomics DNA 130

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

MAY 24, 2021

People who have received two doses of the AstraZeneca or Pfizer/BioNTech COVID-19 vaccines have good protection against the Indian variant of SARS-CoV-2 , according to new UK data. The AZ/Oxford University vaccine was less protective at 60%, lower than its top-line 76% efficacy against the original ‘wild-type’ SARS-CoV-2 strain.

Vaccine 124

Vaccine Vaccination Genome Genomics 124

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Manufacturing 246

Manufacturing Vaccine Vaccination Gene Therapy 246

pharmaphorum

DECEMBER 5, 2022

Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccine 98

Vaccine Vaccination Antibody Allergies 98

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccine 105

Vaccine Vaccination RNA Manufacturing 105

pharmaphorum

AUGUST 10, 2020

The data mining tool will be used to try to unearth some of the many unknowns with the virus, using next-generation sequencing (NGS) to see how the genome of SARS-CoV-2 changes over time, along with patient genetic information, results of lung and CT scans, and other clinical data.

Genetics 136

Genetics Genome Genomics Vaccine 136

XTalks

DECEMBER 23, 2024

Meanwhile, expanded malaria vaccine access in 17 countries offers hope, poised to save tens of thousands of lives annually. Preparing for these events involves strengthening early detection systems, expanding vaccine distribution networks and addressing critical public health gaps. AI continues to play a growing role.

Vaccine 52

Vaccine Vaccination Containment Bacteria 52

STAT News

FEBRUARY 22, 2023

Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines. Moderna will fund preclinical research studies run by the two companies using Life Edit’s tools based on CRISPR technologies that allow scientists to make precise changes to the human genome.

Gene Editing 126

Gene Editing Gene Genetic Disease Research 126

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

STAT News

SEPTEMBER 30, 2022

The shortlist includes researchers who elucidated how cells make energy, those who discovered the chemical chatter of bacteria, many of the brilliant minds who shepherded us into the “ era of the genome ,” and most prominently, the pioneers behind the mRNA Covid vaccines. Read the rest…

Bacteria 124

Bacteria Genome Genomics Vaccination 124

STAT News

NOVEMBER 3, 2022

Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can’t get out of its own way. Read the rest…

Genome 98

Genome Genomics Clinical Trials Clinical Trials 98

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.

Gene 262

Gene Gene Therapy Genetics DNA 262

Scienmag

NOVEMBER 16, 2020

The genomic surveillance system will help public health authorities detect and respond to local outbreaks faster and monitor for viral mutations associated with escape from vaccines once they are deployed The Department for Health and Social Care Testing Innovation Fund has backed the Wellcome Sanger Institute and the COVID-19 Genomics UK (COG-UK) (..)

Genomics 42

Genomics Genome Vaccine Vaccination 42

The Pharma Data

DECEMBER 2, 2020

” VANCOUVER, BC, December 02, 2020 /24-7PressRelease/ — Eyam Vaccines and Immunotherapeutics (EYAM) today announced that former President and CEO of Genome Prairie is joining EYAM. Additional information about Dr. Pontarollo advancement of research projects at Genome Prairie can be found here: [link] … -at-u-of-s.

Vaccine 52

Vaccine Vaccination Genome Genomics 52

The Pharma Data

JANUARY 26, 2021

offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications. has carried out more than half of all SARS-CoV-2 genome sequences submitted to the global database. On Tuesday, the U.K. The offer came as part of the U.K.’s South Africa and Brazil.

Genome 52

Genome Genomics Vaccination Vaccine 52

STAT News

JANUARY 20, 2023

Support for it gained traction as the Covid-19 pandemic highlighted concerns about global vaccine inequity, genomic data-sharing, and more. The December talks productively focused on these issues and concluded with delegates agreeing to another round of negotiation in February.

Genome 119

Genome Genomics Vaccination Vaccine 119

BioSpace

NOVEMBER 15, 2021

This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.

Gene Editing 75

Gene Editing Life Science Genome Genomics 75

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccine 85

Vaccine Vaccination Clinical Trials Clinical Trials 85

pharmaphorum

NOVEMBER 28, 2021

1.1.529 variant of COVID-19 – now christened Omicron – leading vaccine manufacturers have said they are poised to develop new shots if needed. Other vaccine manufacturers have also responded to the new variant. With governments around the world announcing measures to curb the new B.1.1.529

Vaccine 111

Vaccine Vaccination Protein Genetics 111

The Pharma Data

MARCH 7, 2022

Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. IGAs are alterations made using molecular technologies that introduce changes to the genome of an animal. Today, the U.S. Solomon, D.V.M., Related Information.

Genome 52

Genome Genomics Production Marketing 52

Roots Analysis

MARCH 16, 2023

It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases. mRNA Therapeutics and Vaccines Delivery Routes Efficient delivery of both therapeutic and vaccine candidates plays a key role in ensuring the effective expression and presentation of antigens.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Pharmaceutical Technology

JUNE 20, 2023

The proposed institute will focus on vaccine research, public health research, therapeutics, genomics, diagnostics, clinical trials and data. It will be connected across multiple levels to the University of Melbourne’s Doherty Institute.

Biobanking 130

Biobanking Genome Genomics Clinical Trials 130

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Vaccine 111

pharmaphorum

JULY 20, 2022

Prior studies focusing on repetitive sequences of DNA that account for around half of our DNA – sometimes called the ‘repeatome’ and thought to originate from ancient viral infections – have suggested they could interfere with the replication and repair of the genome. billion last year.

DNA 116

DNA Scientist Genome Genomics 116

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc.

Gene Sequencing 97

Gene Sequencing DNA Vaccine Vaccination 97

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Sangamo Therapeutics is the leading patent filer in gene splicing using nucleases.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

pharmaphorum

DECEMBER 20, 2022

Genomic profiling has made it possible to diagnose and treat patients with far greater precision. Often, the initial focus is on participating in the data revolution by expanding genomic sequencing capacity, implementing electronic health records (EHRs), and so on.

Genome 105

Genome Genomics Trials Doctor 105

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. The discovery of shared antigens could lead to the development of vaccines that can be readily used to help a broader group of cancer patients.

Genome 80

Genome Genomics Licensing Licensing 80

pharmaphorum

FEBRUARY 1, 2022

1 strain, and there is somewhat conflicting evidence on its ability to evade the protection from vaccines, according to new studies. That increase was seen regardless of the vaccination status of the secondary cases, and there was an increased risk of spread within vaccinated households with BA.2 The new BA.2 1 and 70% for BA.2

Vaccine 98

Vaccine Vaccination Scientist Genome 98

XTalks

AUGUST 27, 2020

With vaccine trials for COVID-19 ramping up and entering late stages, Johnson & Johnson has announced plans for what will be the largest Phase III trial so far for a vaccine against the novel coronavirus. This is double the enrollment that vaccine makers Moderna and Pfizer have planned for their Phase III trials.

Vaccine 52

Vaccine Vaccination Trials Clinical Trials 52

XTalks

DECEMBER 17, 2021

The year continued to be dominated by COVID-19, and the second year of the pandemic was all about vaccines. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed.

Life Science 98

Life Science Vaccination Vaccine Trials 98

BioPharma Reporter

APRIL 16, 2024

Cytiva has announced the launch of its Xcellerex magnetic mixer â a single-use mixing system designed to address challenges faced by customers engaged in large-scale mAb, vaccine and genomic medicine manufacturing processes.

Genome 52

Genome Genomics Manufacturing Vaccination 52

Scienmag

SEPTEMBER 15, 2020

15, 2020 — Initial findings reported by the Arizona COVID-19 Genomics Union (ACGU) suggest that following Arizona’s first reported case of COVID-19 in late January, the state experienced no cases that went undetected […]. — Sept.

Genome 40

Genome Genomics Allergies Genetics 40

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccine 52

Vaccine Vaccination Allergies Genome 52

Pharmaceutical Technology

DECEMBER 9, 2022

In regards to the latter, notable examples include the acquisition of Cergentis, a genomics-focused biotechnology company based in the Netherlands. The deal allows the company to provide proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Development 130

Development Production Manufacturing Vaccine 130